FRI0627 Inadvertent yellow fever vaccination of patients with immune mediated inflammatory disease in private practice.

Abstract

Background: Yellow Fever (YF) is an endemic disease, in specific areas of Brazil. Since 1942, no new urban cycle cases have been observed. Yet, in early 2017, outbreaks of YF were reported in many states, outside the endemic areas, where YF was not considered a risk. Hence, new and some fatal cases have been reported including in highly populated areas close to the city of Sao Paulo. As it has been widely broadcasted, population searching for vaccination significantly increased and cases of inadvertent vaccination have been registered. Objective(s): To analyze the consequences of inadvertent YF primo-vaccination in patients with immune mediated inflammatory diseases (IMID). Method(s): Observational study (12/2017-01/2018).54 rheumatologists from private practice at different areas of Sao Paulo included specific YF information in their patients' orientations and actively searched for IMID patients that have received YF vaccination (YFV) inputting the data in a web-based questionnaire. Result(s): 56 patients received YFV; female 42 (75%), mean (+/-SD) age= 56+/-14 yr, median disease duration= 7 yr (6 months-45 yr), Diagnosis: RA (n=39; 72%), PsA (n=5), AS (n=4), 2 SLE, 3 vasculitis, 2 SS, one ReA and 2 UA. Treatment: 30 (54%) were considered under current strong immunosuppression (CE-20 mg, MTX>20 mg, leflunomide, tofacitinib and biologic agents (BA); 18 (32%) were on biologic agents (9 anti-TNF, 2 abatacept, 3 tocilizumab, 1 rituximab, 1 patient each secukinumab and tofacitinib). Remaining patients were receiving csDMARDs isolated or in combination, with or without low CE (